

# Eleuterio Ferrannini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3058080/publications.pdf>

Version: 2024-02-01

275  
papers

44,352  
citations

4584

88  
h-index

2512

202  
g-index

359  
all docs

359  
docs citations

359  
times ranked

47467  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mannose as a biomarker of coronary artery disease: Angiographic evidence and clinical significance. <i>International Journal of Cardiology</i> , 2022, 346, 86-92.	0.8	10
2	Tirzepatide as an Insulin Sensitizer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1752-e1753.	1.8	5
3	Initial combination of metformin, sitagliptin, and empagliflozin in drug-naïve patients with type 2 diabetes: Safety and metabolic effects. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 757-762.	2.2	2
4	Role of anatomical location, cellular phenotype and perfusion of adipose tissue in intermediary metabolism: A narrative review. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 43-50.	2.6	9
5	Why Do High-Risk Patients Develop or Not Develop Coronary Artery Disease? Metabolic Insights from the CAPIRE Study. <i>Metabolites</i> , 2022, 12, 123.	1.3	5
6	Hepatic FoxOs link insulin signaling with plasma lipoprotein metabolism through an apolipoprotein M/sphingosine-1-phosphate pathway. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	8
7	Fixed-ratio combination of insulin glargine plus lixisenatide (<sc>iGlarLixi</sc>) improves Ò cell function in people with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1159-1165.	2.2	5
8	Loss of the Incretin Effect in Type 2 Diabetes: A Systematic Review and Meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2092-2100.	1.8	7
9	SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. <i>Trends in Endocrinology and Metabolism</i> , 2022, 33, 424-442.	3.1	23
10	Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS). <i>Diabetes Care</i> , 2022, 45, 1893-1899.	4.3	8
11	Circulating N-Acetylaspartate does not track brain NAA concentrations, cognitive function or features of small vessel disease in humans. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
12	Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	4
13	Differential metabolomic signatures of declining renal function in Types 1 and 2 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1859-1866.	0.4	4
14	Gamma-glutamyltransferase, arterial remodeling and prehypertension in a healthy population at low cardiometabolic risk. <i>Journal of Human Hypertension</i> , 2021, 35, 334-342.	1.0	0
15	Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2021, 114, 154415.	1.5	11
16	Genome-Wide Association Analysis of Pancreatic Beta-Cell Glucose Sensitivity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 80-90.	1.8	5
17	A Journey in Diabetes: From Clinical Physiology to Novel Therapeutics: The 2020 Banting Medal for Scientific Achievement Lecture. <i>Diabetes</i> , 2021, 70, 338-346.	0.3	14
18	Insulin Resistance Is Associated With Enhanced Brain Glucose Uptake During Euglycemic Hyperinsulinemia: A Large-Scale PET Cohort. <i>Diabetes Care</i> , 2021, 44, 788-794.	4.3	31

#	ARTICLE	IF	CITATIONS
19	Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1269-1283.	1.8	24
20	Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?. <i>Diabetes Care</i> , 2021, 44, 641-646.	4.3	10
21	Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1505-1517.	2.2	42
22	HDL Containing Apolipoprotein C-III is Associated with Insulin Sensitivity: A Multicenter Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2928-e2940.	1.8	12
23	Response to Comment on Ferrannini and Rosenstock. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? <i>Diabetes Care</i> 2021;44:641-646. <i>Diabetes Care</i> , 2021, 44, e155-e155.	4.3	0
24	New Insights on the Interactions Between Insulin Clearance and the Main Glucose Homeostasis Mechanisms. <i>Diabetes Care</i> , 2021, 44, 2115-2123.	4.3	16
25	Metabolomic correlates of coronary atherosclerosis, cardiovascular risk, both or neither. Results of the 2 Å– 2 phenotypic CAPIRE study. <i>International Journal of Cardiology</i> , 2021, 336, 14-21.	0.8	9
26	Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2632-2642.	2.2	30
27	Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 502-514.	5.5	53
28	Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence. <i>Cardiovascular Diabetology</i> , 2021, 20, 196.	2.7	28
29	Association of artificially sweetened and sugar-sweetened soft drinks with Î²-cell function, insulin sensitivity, and type 2 diabetes: the Maastricht Study. <i>European Journal of Nutrition</i> , 2020, 59, 1717-1727.	1.8	12
30	Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 393-403.	2.2	53
31	Hormone substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION 8 study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 99-106.	2.2	5
32	Anti-inflammatory properties of antidiabetic drugs: A compromised land in the COVID-19 era?. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107723.	1.2	58
33	Liver nucleotide biosynthesis is linked to protection from vascular complications in individuals with long-term type 1 diabetes. <i>Scientific Reports</i> , 2020, 10, 11561.	1.6	8
34	Insulin enhances renal glucose excretion: relation to insulin sensitivity and sodium-glucose cotransport. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001178.	1.2	8
35	Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2020, 43, 1813-1821.	4.3	19
36	Brain substrate metabolism and Î²-cell function in humans: A positron emission tomography study. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00136.	1.0	11

#	ARTICLE	IF	CITATIONS
37	Mechanisms of Sodium-Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics. <i>Diabetes Care</i> , 2020, 43, 2183-2189.	4.3	35
38	New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective. <i>Metabolism: Clinical and Experimental</i> , 2020, 107, 154218.	1.5	10
39	Fixed-dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1001-1005.	2.2	7
40	Brain free fatty acid uptake is elevated in morbid obesity, and is irreversible 6-months after bariatric surgery: A positron emission tomography study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1074-1082.	2.2	27
41	Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study. <i>Diabetes Care</i> , 2020, 43, 843-851.	4.3	34
42	Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea. <i>Endocrinology and Metabolism</i> , 2020, 35, 329-338.	1.3	7
43	SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes. <i>Clinical Science</i> , 2020, 134, 3107-3118.	1.8	19
44	Brain glucose uptake is associated with endogenous glucose production in obese patients before and after bariatric surgery and predicts metabolic outcome at follow-up. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 218-226.	2.2	36
45	Renal hemodynamics and fatty acid uptake: effects of obesity and weight loss. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E871-E878.	1.8	25
46	Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2019, 42, e42-e44.	4.3	25
47	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. <i>Diabetes Care</i> , 2019, 42, 1147-1154.	4.3	249
48	Quantification of d-mannose in plasma: Development and validation of a reliable and accurate HPLC-MS-MS method. <i>Clinica Chimica Acta</i> , 2019, 493, 31-35.	0.5	10
49	Spontaneous ketonuria and risk of incident diabetes: a 12-year prospective study. <i>Diabetologia</i> , 2019, 62, 779-788.	2.9	11
50	The diabetes pandemic and associated infections: suggestions for clinical microbiology. <i>Reviews in Medical Microbiology</i> , 2019, 30, 1-17.	0.4	98
51	Prospective associations of dietary carbohydrate, fat, and protein intake with $\beta$ -cell function in the CODAM study. <i>European Journal of Nutrition</i> , 2019, 58, 597-608.	1.8	7
52	Nocturnal hypertension in diabetes: Potential target of sodium/glucose cotransporter 2 (SGLT2) inhibition. <i>Journal of Clinical Hypertension</i> , 2018, 20, 424-428.	1.0	17
53	Prediction of clamp-derived insulin sensitivity from the oral glucose insulin sensitivity index. <i>Diabetologia</i> , 2018, 61, 1135-1141.	2.9	45
54	Overview of Glucose Homeostasis. <i>Endocrinology</i> , 2018, , 1-23.	0.1	0

#	ARTICLE	IF	CITATIONS
55	Sleeping oxygen saturation, rapid eye movement sleep, and the adaptation of postprandial metabolic function in insulin sensitive and resistant individuals without diabetes. <i>Physiology and Behavior</i> , 2018, 191, 123-130.	1.0	1
56	Hypertension and Diabetes Mellitus. <i>Hypertension</i> , 2018, 71, 422-428.	1.3	179
57	Elevated Plasma Levels of 3-Hydroxyisobutyric Acid Are Associated With Incident Type 2 Diabetes. <i>EBioMedicine</i> , 2018, 27, 151-155.	2.7	53
58	High density lipoprotein with apolipoprotein C-III is associated with carotid intima-media thickness among generally healthy individuals. <i>Atherosclerosis</i> , 2018, 269, 92-99.	0.4	11
59	Slope of change in HbA <sub>1c</sub> from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism</i> , 2018, 1, e00016.	1.0	12
60	Insulin resistance and cardiovascular outcomes in the <i>ORIGIN</i> trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 564-570.	2.2	10
61	Defective Amplifying Pathway of $\beta$ -Cell Secretory Response to Glucose in Type 2 Diabetes: Integrated Modeling of In Vitro and In Vivo Evidence. <i>Diabetes</i> , 2018, 67, 496-506.	0.3	20
62	How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. <i>Diabetes Care</i> , 2018, 41, 356-363.	4.3	534
63	Overview of Glucose Homeostasis. <i>Endocrinology</i> , 2018, , 1-22.	0.1	0
64	Metabolomic Profile Predicts Development of Microalbuminuria in Individuals with Type 1 Diabetes. <i>Scientific Reports</i> , 2018, 8, 13853.	1.6	50
65	Adipose tissue and skeletal muscle insulin-mediated glucose uptake in insulin resistance: role of blood flow and diabetes. <i>American Journal of Clinical Nutrition</i> , 2018, 108, 749-758.	2.2	43
66	microRNA-205-5p is a modulator of insulin sensitivity that inhibits FOXO function. <i>Molecular Metabolism</i> , 2018, 17, 49-60.	3.0	29
67	Triglyceride-rich very low-density lipoproteins (VLDL) are independently associated with insulin secretion in a multiethnic cohort of adolescents. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2905-2910.	2.2	16
68	Effects of acute NEFA manipulation on incretin-induced insulin secretion in participants with and without type 2 diabetes. <i>Diabetologia</i> , 2018, 61, 1829-1837.	2.9	13
69	Short Course of Insulin Treatment versus Metformin in Newly Diagnosed Patients with Type 2 Diabetes. <i>Journal of Clinical Medicine</i> , 2018, 7, 235.	1.0	4
70	Identification, pathophysiology, and clinical implications of primary insulin hypersecretion in nondiabetic adults and adolescents. <i>JCI Insight</i> , 2018, 3, .	2.3	87
71	Insulin resistance and normal thyroid hormone levels: prospective study and metabolomic analysis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2017, 312, E429-E436.	1.8	29
72	Cardiovascular safety of insulin: Between real-world data and reality. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1201-1204.	2.2	8

#	ARTICLE	IF	CITATIONS
73	Fatty acid uptake and blood flow in adipose tissue compartments of morbidly obese subjects with or without type 2 diabetes: effects of bariatric surgery. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2017, 313, E175-E182.	1.8	26
74	Sodium-glucose co-transporter ( SGLT )2 and SGLT1 renal expression in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1289-1294.	2.2	66
75	Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology. <i>Cell Metabolism</i> , 2017, 26, 27-38.	7.2	233
76	Effect of exenatide on postprandial glucose fluxes, lipolysis, and $\beta$ -cell function in non-diabetic, morbidly obese patients. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 412-420.	2.2	15
77	Mechanisms linking empagliflozin to cardiovascular and renal protection. <i>International Journal of Cardiology</i> , 2017, 241, 450-456.	0.8	36
78	Renal Handling of Ketones in Response to Sodium-glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, 771-776.	4.3	127
79	Discriminatory ability of simple OGTT-based beta cell function indices for prediction of prediabetes and type 2 diabetes: the CODAM study. <i>Diabetologia</i> , 2017, 60, 432-441.	2.9	36
80	SGLT inhibition in T1DM - definite benefit with manageable risk. <i>Nature Reviews Endocrinology</i> , 2017, 13, 698-699.	4.3	6
81	Diabetes Research and Care Through the Ages. <i>Diabetes Care</i> , 2017, 40, 1302-1313.	4.3	11
82	Muscle and adipose tissue morphology, insulin sensitivity and beta-cell function in diabetic and nondiabetic obese patients: effects of bariatric surgery. <i>Scientific Reports</i> , 2017, 7, 9007.	1.6	62
83	Plasma Mannose Levels Are Associated with Incident Type 2 Diabetes and Cardiovascular Disease. <i>Cell Metabolism</i> , 2017, 26, 281-283.	7.2	85
84	GLP-1 response to sequential mixed meals: influence of insulin resistance. <i>Clinical Science</i> , 2017, 131, 2901-2910.	1.8	9
85	Associations of Dietary Glucose, Fructose, and Sucrose with $\beta$ -Cell Function, Insulin Sensitivity, and Type 2 Diabetes in the Maastricht Study. <i>Nutrients</i> , 2017, 9, 380.	1.7	15
86	Response to Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. <i>Diabetes Care</i> 2016;39:1108-1114. <i>Diabetes Care</i> , 2016, 39, e226-e226.	4.3	4
87	Response to Comment on Ferrannini et al. <i>Diabetes Care</i> 2016;39:1108-1114. Comment on Mudaliar et al. <i>Diabetes Care</i> 2016;39:1115-1122. <i>Diabetes Care</i> , 2016, 39, e196-e197.	4.3	3
88	$\beta$ -Hydroxybutyric Acid Is a Selective Metabolite Biomarker of Impaired Glucose Tolerance. <i>Diabetes Care</i> , 2016, 39, 988-995.	4.3	93
89	Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a <i>Diabetes Care</i> Editors' Expert Forum. <i>Diabetes Care</i> , 2016, 39, 1186-1201.	4.3	113
90	Risk Factors for Spontaneously Self-Reported Postprandial Hypoglycemia After Bariatric Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3600-3607.	1.8	27

#	ARTICLE	IF	CITATIONS
91	Impact of a mild decrease in fasting plasma glucose on $\beta$ -cell function in healthy subjects and patients with type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 310, E919-E924.	1.8	5
92	Integrated Network Analysis Reveals an Association between Plasma Mannose Levels and Insulin Resistance. <i>Cell Metabolism</i> , 2016, 24, 172-184.	7.2	133
93	CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. <i>Diabetes Care</i> , 2016, 39, 1108-1114.	4.3	774
94	Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. <i>Diabetes</i> , 2016, 65, 1190-1195.	0.3	498
95	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016, 48, 333-342.	0.4	56
96	Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes. <i>Diabetologia</i> , 2016, 59, 700-708.	2.9	21
97	Prediction of Declining Renal Function and Albuminuria in Patients With Type 2 Diabetes by Metabolomics. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 696-704.	1.8	62
98	Regulation of Intermediary Metabolism During Fasting and Feeding. , 2016, , 598-626.e3.		3
99	Type 2 diabetes mellitus. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15019.	18.1	1,308
100	Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. <i>European Heart Journal</i> , 2015, 36, 2288-2296.	1.0	210
101	Increased Bile Acid Synthesis and Deconjugation After Biliopancreatic Diversion. <i>Diabetes</i> , 2015, 64, 3377-3385.	0.3	66
102	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetologia</i> , 2015, 58, 429-442.	2.9	598
103	New genetic loci link adipose and insulin biology to body fat distribution. <i>Nature</i> , 2015, 518, 187-196.	13.7	1,328
104	Genetic studies of body mass index yield new insights for obesity biology. <i>Nature</i> , 2015, 518, 197-206.	13.7	3,823
105	Identifying glucose thresholds for incident diabetes by physiological analysis: a mathematical solution. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2015, 308, R590-R596.	0.9	5
106	Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. <i>Diabetes Care</i> , 2015, 38, 1730-1735.	4.3	276
107	Influence of endogenous NEFA on beta cell function in humans. <i>Diabetologia</i> , 2015, 58, 2344-2351.	2.9	27
108	Adaptation of $\beta$ -Cell and Endothelial Function to Carbohydrate Loading: Influence of Insulin Resistance. <i>Diabetes</i> , 2015, 64, 2550-2559.	0.3	10

#	ARTICLE	IF	CITATIONS
109	A Novel Insulin Resistance Index to Monitor Changes in Insulin Sensitivity and Glucose Tolerance: the ACT NOW Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1855-1862.	1.8	24
110	Of Microbes and Men: Figure 1. <i>Diabetes Care</i> , 2015, 38, 1817-1819.	4.3	3
111	Mechanisms through which a small protein and lipid preload improves glucose tolerance. <i>Diabetologia</i> , 2015, 58, 2503-2512.	2.9	41
112	Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. <i>Diabetes Care</i> , 2015, 38, 1638-1642.	4.3	513
113	The past 10 yearsâ€™ new hormones, new functions, new endocrine organs. <i>Nature Reviews Endocrinology</i> , 2015, 11, 681-686.	4.3	12
114	Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. <i>Diabetes Care</i> , 2015, 38, 140-149.	4.3	2,326
115	A Novel Test for IGT Utilizing Metabolite Markers of Glucose Tolerance. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 69-76.	1.3	39
116	Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. <i>Journal of Clinical Investigation</i> , 2014, 124, 499-508.	3.9	907
117	Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. <i>World Journal of Diabetes</i> , 2014, 5, 586.	1.3	83
118	Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. <i>Diabetologia</i> , 2014, 57, 891-901.	2.9	96
119	Residual macrovascular risk in 2013: what have we learned?. <i>Cardiovascular Diabetology</i> , 2014, 13, 26.	2.7	149
120	Chemokine (Câ€“Xâ€“C motif) ligand (CXCL)10 in autoimmune diseases. <i>Autoimmunity Reviews</i> , 2014, 13, 272-280.	2.5	448
121	Extra-ocular muscle cells from patients with Graves' ophthalmopathy secrete $\hat{1}\pm$ (CXCL10) and $\hat{1}^2$ (CCL2) chemokines under the influence of cytokines that are modulated by PPAR $\hat{1}^3$ . <i>Autoimmunity Reviews</i> , 2014, 13, 1160-1166.	2.5	27
122	$\hat{1}^2$ -Cell Function, Incretin Effect, and Incretin Hormones in Obese Youth Along the Span of Glucose Tolerance From Normal to Prediabetes to Type 2 Diabetes. <i>Diabetes</i> , 2014, 63, 3846-3855.	0.3	79
123	$\hat{1}^2$ -Cell function in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 1217-1227.	1.5	111
124	The threshold shift paradigm of obesity: evidence from surgically induced weight loss. <i>American Journal of Clinical Nutrition</i> , 2014, 100, 996-1002.	2.2	27
125	The Target of Metformin in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2014, 371, 1547-1548.	13.9	113
126	Defining the role of common variation in the genomic and biological architecture of adult human height. <i>Nature Genetics</i> , 2014, 46, 1173-1186.	9.4	1,818



#	ARTICLE	IF	CITATIONS
127	Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic. <i>Diabetologia</i> , 2014, 57, 1199-1203.	2.9	46
128	CXCR3, CXCL10 and type 1 diabetes. <i>Cytokine and Growth Factor Reviews</i> , 2014, 25, 57-65.	3.2	99
129	Definition of intervention points in prediabetes. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 667-675.	5.5	52
130	Common Genetic Variants Highlight the Role of Insulin Resistance and Body Fat Distribution in Type 2 Diabetes, Independent of Obesity. <i>Diabetes</i> , 2014, 63, 4378-4387.	0.3	153
131	Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2013, 36, 1779-1788.	4.3	130
132	Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 268-273.	1.2	76
133	Antibodies recognizing specific <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> 's MAP3738c protein in type 1 diabetes mellitus children are associated with serum Th1 (CXCL10) chemokine. <i>Cytokine</i> , 2013, 61, 337-339.	1.4	17
134	Early Metabolic Markers of the Development of Dysglycemia and Type 2 Diabetes and Their Physiological Significance. <i>Diabetes</i> , 2013, 62, 1730-1737.	0.3	307
135	Parental history of type 2 diabetes, TCF7L2 variant and lower insulin secretion are associated with incident hypertension. Data from the DESIR and RISC cohorts. <i>Diabetologia</i> , 2013, 56, 2414-2423.	2.9	22
136	Biliopancreatic Diversion in Nonobese Patients With Type 2 Diabetes: Impact and Mechanisms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2765-2773.	1.8	57
137	Renal Glucose Handling. <i>Diabetes Care</i> , 2013, 36, 1260-1265.	4.3	70
138	Insulin Sensitivity and Carotid Intima-Media Thickness. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1409-1417.	1.1	47
139	Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin. <i>Diabetes Care</i> , 2013, 36, 4015-4021.	4.3	187
140	Long-Term Effects of Bariatric Surgery on Meal Disposal and $\beta$ -Cell Function in Diabetic and Nondiabetic Patients. <i>Diabetes</i> , 2013, 62, 3709-3717.	0.3	98
141	Influence of Apolipoproteins on the Association Between Lipids and Insulin Sensitivity. <i>Diabetes Care</i> , 2013, 36, 4125-4131.	4.3	19
142	Age, Renal Dysfunction, Cardiovascular Disease, and Antihyperglycemic Treatment in Type 2 Diabetes Mellitus: Findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 1253-1261.	1.3	65
143	Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes. <i>PLoS ONE</i> , 2013, 8, e73154.	1.1	38
144	Sweetened beverages intake, hyperuricemia and metabolic syndrome. <i>The Mexico City Diabetes Study. Salud Publica De Mexico</i> , 2013, 55, 557.	0.1	10

#	ARTICLE	IF	CITATIONS
145	Diabetes and hypertension: the bad companions. <i>Lancet, The</i> , 2012, 380, 601-610.	6.3	498
146	SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. <i>Nature Reviews Endocrinology</i> , 2012, 8, 495-502.	4.3	364
147	Estimation of prehepatic insulin secretion: comparison between standardized C-peptide and insulin kinetic models. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 434-443.	1.5	18
148	Mechanisms for the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2818-2826.	1.8	91
149	Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. <i>Cytokine</i> , 2012, 59, 218-222.	1.4	26
150	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. <i>Diabetes Care</i> , 2012, 35, 1364-1379.	4.3	3,077
151	Physiology of Glucose Homeostasis and Insulin Therapy in Type 1 and Type 2 Diabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2012, 41, 25-39.	1.2	21
152	Pathophysiology: Loss of $\beta$ -Cell Function. , 2012, , 11-29.		0
153	Pathophysiology of $\beta$ -Prediabetes. <i>Medical Clinics of North America</i> , 2011, 95, 327-339.	1.1	124
154	Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10. <i>Cytokine</i> , 2011, 55, 288-293.	1.4	60
155	Influence of Hyperinsulinemia and Insulin Resistance on In Vivo $\beta$ -Cell Function. <i>Diabetes</i> , 2011, 60, 3141-3147.	0.3	43
156	Cytokines (interferon- $\gamma$ and tumor necrosis factor- $\alpha$ )-induced nuclear factor- $\kappa$ B activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 277-283.	1.5	34
157	Peroxisome proliferator-activated receptor $\alpha$ agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease. <i>Experimental Cell Research</i> , 2011, 317, 1527-1533.	1.2	23
158	Improvement in Insulin Sensitivity and $\beta$ -Cell Function Following Ileal Interposition with Sleeve Gastrectomy in Type 2 Diabetic Patients: Potential Mechanisms. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 1344-1353.	0.9	50
159	Increase of Circulating CXCL9 and CXCL11 Associated with Euthyroid or Subclinically Hypothyroid Autoimmune Thyroiditis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1859-1863.	1.8	59
160	Body Weight, Not Insulin Sensitivity or Secretion, May Predict Spontaneous Weight Changes in Nondiabetic and Prediabetic Subjects. <i>Diabetes</i> , 2011, 60, 1938-1945.	0.3	20
161	Learning From Glycosuria. <i>Diabetes</i> , 2011, 60, 695-696.	0.3	35
162	Progression to Diabetes in Relatives of Type 1 Diabetic Patients: Mechanisms and Mode of Onset. <i>Diabetes</i> , 2010, 59, 679-685.	0.3	120

#	ARTICLE	IF	CITATIONS
163	CXCL9 and CXCL11 Chemokines Modulation by Peroxisome Proliferator-Activated Receptor- $\beta$ Agonists Secretion in Gravesâ€™ and Normal Thyrocytes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, E413-E420.	1.8	61
164	$\beta$ -Hydroxybutyrate Is an Early Biomarker of Insulin Resistance and Glucose Intolerance in a Nondiabetic Population. <i>PLoS ONE</i> , 2010, 5, e10883.	1.1	594
165	Fatty Acid Metabolism in the Liver, Measured by Positron Emission Tomography, Is Increased in Obese Individuals. <i>Gastroenterology</i> , 2010, 139, 846-856.e6.	0.6	144
166	Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise. <i>Diabetes Care</i> , 2010, 33, 2217-2224.	4.3	628
167	The Stunned $\beta$ Cell: A Brief History. <i>Cell Metabolism</i> , 2010, 11, 349-352.	7.2	154
168	Regulation of Intermediary Metabolism During Fasting and Feeding. , 2010, , 673-698.		5
169	Monokine Induced by Interferon $\beta$ (IFN $\beta$ ) (CXCL9) and IFN $\beta$ Inducible T-Cell $\beta$ -Chemoattractant (CXCL11) Involvement in Gravesâ€™ Disease and Ophthalmopathy: Modulation by Peroxisome Proliferator-Activated Receptor- $\beta$ Agonists. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1803-1809.	1.8	91
170	Impact of Different Bariatric Surgical Procedures on Insulin Action and $\beta$ -Cell Function in Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 514-520.	4.3	160
171	Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 297, E225-E230.	1.8	27
172	Redefining the Diagnosis of Diabetes Using Glycated Hemoglobin. <i>Diabetes Care</i> , 2009, 32, 1344-1345.	4.3	33
173	Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 297, E532-E537.	1.8	74
174	Insulin resistance versus $\beta$ -cell dysfunction in the pathogenesis of type 2 diabetes. <i>Current Diabetes Reports</i> , 2009, 9, 188-189.	1.7	4
175	Thiazolidinediones and antiproliferatives in primary human anaplastic thyroid cancer cells. <i>Clinical Endocrinology</i> , 2009, 70, 946-953.	1.2	63
176	CXCL10 and CCL2 Chemokine Serum Levels in Patients With Hepatitis C Associated With Autoimmune Thyroiditis. <i>Journal of Interferon and Cytokine Research</i> , 2009, 29, 345-352.	0.5	12
177	Metabolic characteristics of prehypertension: role of classification criteria and gender. <i>Journal of Hypertension</i> , 2009, 27, 2394-2402.	0.3	27
178	Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. <i>Clinical Endocrinology</i> , 2008, 69, 148-152.	1.2	63
179	$\beta$ -Chemokine CXCL10 and $\beta$ -chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. <i>Metabolism: Clinical and Experimental</i> , 2008, 57, 1270-1277.	1.5	44
180	Quantification of liver perfusion with [ $^{15}$ O]H $_2$ O-PET and its relationship with glucose metabolism and substrate levels. <i>Journal of Hepatology</i> , 2008, 48, 974-982.	1.8	16

#	ARTICLE	IF	CITATIONS
181	High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. <i>Cytokine</i> , 2008, 42, 137-143.	1.4	56
182	Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. <i>European Journal of Endocrinology</i> , 2008, 159, 283-291.	1.9	55
183	Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients. <i>Diabetes</i> , 2008, 57, 1340-1348.	0.3	353
184	High Values of CXCL10 Serum Levels in Mixed Cryoglobulinemia Associated With Hepatitis C Infection. <i>American Journal of Gastroenterology</i> , 2008, 103, 2488-2494.	0.2	61
185	Early Hypertension Is Associated With Reduced Regional Cardiac Function, Insulin Resistance, Epicardial, and Visceral Fat. <i>Hypertension</i> , 2008, 51, 282-288.	1.3	107
186	Recurrence of Cardiovascular Events in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 2154-2159.	4.3	71
187	High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. <i>Autoimmunity</i> , 2008, 41, 537-542.	1.2	41
188	Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 182-187.	3.0	135
189	Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3671-3689.	1.8	164
190	Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis. <i>Journal of Rheumatology</i> , 2008, 35, 1809-11.	1.0	27
191	Common Variants of the Novel Type 2 Diabetes Genes <i>CDKAL1</i> and <i>HHEX/IDE</i> Are Associated With Decreased Pancreatic $\beta$ -Cell Function. <i>Diabetes</i> , 2007, 56, 3101-3104.	0.3	226
192	$\beta$ -Cell Function in Severely Obese Type 2 Diabetic Patients: Long-term effects of bariatric surgery. <i>Diabetes Care</i> , 2007, 30, 1002-1004.	4.3	49
193	Thiazolidinediones improve $\beta$ -cell function in type 2 diabetic patients. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 292, E871-E883.	1.8	167
194	Insulin Resistance, Insulin Response, and Obesity as Indicators of Metabolic Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2885-2892.	1.8	149
195	Incidence and Risk Factors for Stroke in Type 2 Diabetic Patients. <i>Stroke</i> , 2007, 38, 1154-1160.	1.0	98
196	Iodine-131 Given for Therapeutic Purposes Modulates Differently Interferon- $\gamma$ -Inducible $\beta$ -Chemokine CXCL10 Serum Levels in Patients with Active Graves' Disease or Toxic Nodular Goiter. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1485-1490.	1.8	67
197	Metabolic Syndrome: A Solution in Search of a Problem. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 396-398.	1.8	68
198	Incidence of Coronary Heart Disease in Type 2 Diabetic Men and Women: Impact of microvascular complications, treatment, and geographic location. <i>Diabetes Care</i> , 2007, 30, 1241-1247.	4.3	144

#	ARTICLE	IF	CITATIONS
199	Thyroid Cancer in HCV-Related Chronic Hepatitis Patients: A Case-Control Study. <i>Thyroid</i> , 2007, 17, 447-451.	2.4	66
200	Quantification of Liver Glucose Metabolism by Positron Emission Tomography: Validation Study in Pigs. <i>Gastroenterology</i> , 2007, 132, 531-542.	0.6	61
201	Relationship Between Hepatic/Visceral Fat and Hepatic Insulin Resistance in Nondiabetic and Type 2 Diabetic Subjects. <i>Gastroenterology</i> , 2007, 133, 496-506.	0.6	500
202	Is insulin resistance atherogenic? A review of the evidence. <i>Atherosclerosis Supplements</i> , 2006, 7, 5-10.	1.2	38
203	Is insulin resistance the cause of the metabolic syndrome?. <i>Annals of Medicine</i> , 2006, 38, 42-51.	1.5	56
204	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2006, 28, 88-136.	1.0	1,144
205	Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing. <i>Cytokine</i> , 2006, 34, 32-38.	1.4	73
206	Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. <i>Clinical Endocrinology</i> , 2006, 64, 189-195.	1.2	67
207	Fasting-based Estimates of Insulin Sensitivity in Overweight and Obesity: A Critical Appraisal. <i>Obesity</i> , 2006, 14, 1250-1256.	1.5	29
208	Interferon- $\gamma$ -Inducible $\beta$ -Chemokine CXCL10 Involvement in Graves' Ophthalmopathy: Modulation by Peroxisome Proliferator-Activated Receptor- $\beta$ Agonists. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 614-620.	1.8	144
209	Impact of incretin hormones on $\beta$ -cell function in subjects with normal or impaired glucose tolerance. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 291, E1144-E1150.	1.8	76
210	Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. <i>European Journal of Endocrinology</i> , 2006, 154, 651-658.	1.9	70
211	The Effect of Pioglitazone on the Liver: Role of adiponectin. <i>Diabetes Care</i> , 2006, 29, 2275-2281.	4.3	76
212	Clustering of Insulin Resistance With Vascular Dysfunction and Low-Grade Inflammation in Type 2 Diabetes. <i>Diabetes</i> , 2006, 55, 1133-1140.	0.3	170
213	$^{18}\text{F}$ -FDG assessment of glucose disposal and production rates during fasting and insulin stimulation: a validation study. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1016-22.	2.8	33
214	Predictors of weight loss and reversal of comorbidities in malabsorptive bariatric surgery. <i>American Journal of Clinical Nutrition</i> , 2005, 81, 1292-1297.	2.2	59
215	Identification of Individuals With Insulin Resistance Using Routine Clinical Measurements. <i>Diabetes</i> , 2005, 54, 333-339.	0.3	324
216	Increase of interferon- $\gamma$ inducible $\beta$ chemokine CXCL10 but not $\beta$ chemokine CCL2 serum levels in chronic autoimmune thyroiditis. <i>European Journal of Endocrinology</i> , 2005, 152, 171-177.	1.9	82

#	ARTICLE	IF	CITATIONS
217	$\beta$ -Cell Function in Subjects Spanning the Range from Normal Glucose Tolerance to Overt Diabetes: A New Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 493-500.	1.8	470
218	Rosiglitazone Treatment Increases Subcutaneous Adipose Tissue Glucose Uptake in Parallel with Perfusion in Patients with Type 2 Diabetes: A Double-Blind, Randomized Study with Metformin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6523-6528.	1.8	31
219	Increased Fat Mass Compensates for Insulin Resistance in Abdominal Obesity and Type 2 Diabetes: A Positron-Emitting Tomography Study. <i>Diabetes</i> , 2005, 54, 2720-2726.	0.3	99
220	Hepatitis C Virus Infection: Evidence for an association with type 2 diabetes. <i>Diabetes Care</i> , 2005, 28, 2548-2550.	4.3	114
221	$\beta$ -Cell Function in Morbidly Obese Subjects During Free Living: Long-Term Effects of Weight Loss. <i>Diabetes</i> , 2005, 54, 2382-2389.	0.3	88
222	$\beta$ -Cell Function in Mild Type 2 Diabetic Patients: Effects of 6-month glucose lowering with nateglinide. <i>Diabetes Care</i> , 2005, 28, 1132-1138.	4.3	25
223	Differential effect of weight loss on insulin resistance in surgically treated obese patients. <i>American Journal of Medicine</i> , 2005, 118, 51-57.	0.6	123
224	Separate Contribution of Diabetes, Total Fat Mass, and Fat Topography to Glucose Production, Gluconeogenesis, and Glycogenolysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3914-3921.	1.8	103
225	Defective Liver Disposal of Free Fatty Acids in Patients with Impaired Glucose Tolerance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3496-3502.	1.8	36
226	High Levels of Circulating CXC Chemokine Ligand 10 Are Associated with Chronic Autoimmune Thyroiditis and Hypothyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5496-5499.	1.8	108
227	Visceral Fat in Hypertension. <i>Hypertension</i> , 2004, 44, 127-133.	1.3	239
228	Mode of Onset of Type 2 Diabetes from Normal or Impaired Glucose Tolerance. <i>Diabetes</i> , 2004, 53, 160-165.	0.3	129
229	Vascular Effects of Improving Metabolic Control With Metformin or Rosiglitazone in Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 1349-1357.	4.3	170
230	Beta-Cell Function in Obesity: Effects of Weight Loss. <i>Diabetes</i> , 2004, 53, S26-S33.	0.3	114
231	Effect of PPAR- $\alpha$ Activation and Inhibition on Glucose-Stimulated Insulin Release in INS-1e Cells. <i>Diabetes</i> , 2004, 53, S79-S83.	0.3	35
232	Liver uptake of free fatty acids in vivo in humans as determined with $^{14}$ (R,S)-[18 F]fluoro-6-thia-heptadecanoic acid and PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1160-1164.	3.3	22
233	Insulin-Mediated Hepatic Glucose Uptake Is Impaired in Type 2 Diabetes: Evidence for a Relationship with Glycemic Control. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2055-2060.	1.8	73
234	Influence of Ethnicity and Familial Diabetes on Glucose Tolerance and Insulin Action: A Physiological Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3251-3257.	1.8	39

#	ARTICLE	IF	CITATIONS
235	Effect of Acute Hyperglycemia on Insulin Secretion in Humans. <i>Diabetes</i> , 2002, 51, S130-S133.	0.3	77
236	Independent Association of Type 2 Diabetes and Coronary Artery Disease With Myocardial Insulin Resistance. <i>Diabetes</i> , 2002, 51, 3020-3024.	0.3	144
237	Insulin Resistance in Morbid Obesity: Reversal With Intramyocellular Fat Depletion. <i>Diabetes</i> , 2002, 51, 144-151.	0.3	464
238	Meal and oral glucose tests for assessment of $\beta$ -cell function: modeling analysis in normal subjects. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002, 283, E1159-E1166.	1.8	267
239	Assessing Insulin Secretion by Modeling in Multiple-Meal Tests: Role of Potentiation. <i>Diabetes</i> , 2002, 51, S221-S226.	0.3	209
240	Regional myocardial blood flow and glucose utilization during fasting and physiological hyperinsulinemia in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002, 282, E1163-E1171.	1.8	48
241	Hyperinsulinemia and Autonomic Nervous System Dysfunction in Obesity. <i>Circulation</i> , 2001, 103, 513-519.	1.6	209
242	Dose-response characteristics of insulin action on glucose metabolism: a non-steady-state approach. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2000, 278, E794-E801.	1.8	82
243	Insulin prolongs the QTc interval in humans. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2000, 279, R2022-R2025.	0.9	70
244	Effect of Vitamin C on Forearm Blood Flow and Glucose Metabolism in Essential Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 2401-2406.	1.1	23
245	Independent Influence of Age on Basal Insulin Secretion in Nondiabetic Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 863-868.	1.8	199
246	Autonomic and Hemodynamic Responses to Insulin in Lean and Obese Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2084-2090.	1.8	105
247	Insulin Resistance versus Insulin Deficiency in Non-Insulin-Dependent Diabetes Mellitus: Problems and Prospects. <i>Endocrine Reviews</i> , 1998, 19, 477-490.	8.9	371
248	How to measure insulin sensitivity. <i>Journal of Hypertension</i> , 1998, 16, 895-906.	0.3	405
249	Metabolic and Cardiovascular Assessment in Moderate Obesity: Effect of Weight Loss. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 2937-2943.	1.8	51
250	Insulin resistance is central to the burden of diabetes. , 1997, 13, 81-86.		56
251	Insulin resistance is central to the burden of diabetes. , 1997, 13, 81.		3
252	Insulin Sensitivity, Vascular Reactivity, and Clamp-Induced Vasodilatation in Essential Hypertension. <i>Circulation</i> , 1997, 96, 849-855.	1.6	57

#	ARTICLE	IF	CITATIONS
253	Insulin Resistance, Hyperinsulinemia, and Blood Pressure. <i>Hypertension</i> , 1997, 30, 1144-1149.	1.3	246
254	Effect of insulin on renal sodium and uric acid handling in essential hypertension. <i>American Journal of Hypertension</i> , 1996, 9, 746-752.	1.0	248
255	In vivo effect of insulin on intracellular calcium concentrations: Relation to insulin resistance. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 1402-1407.	1.5	36
256	Effect of Insulin on Acetylcholine-Induced Vasodilation in Normotensive Subjects and Patients With Essential Hypertension. <i>Circulation</i> , 1995, 92, 2911-2918.	1.6	147
257	Insulin sensitivity in familial hypercholesterolemia. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 1359-1364.	1.5	23
258	Insulin Resistance of Stress: Sites and Mechanisms. <i>Clinical Science</i> , 1993, 85, 525-535.	1.8	53
259	The haemodynamics of obesity: a theoretical analysis. <i>Journal of Hypertension</i> , 1992, 10, 1417-1423.	0.3	42
260	Coronary hemodynamics and myocardial metabolism in patients with syndrome X: Response to pacing stress. <i>Journal of the American College of Cardiology</i> , 1991, 17, 1461-1470.	1.2	205
261	The Role of Free Fatty Acid Metabolism in the Pathogenesis of Insulin Resistance in Obesity and Noninsulin-Dependent Diabetes Mellitus*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 72, 96-107.	1.8	304
262	Hepatic glucose production in insulin-resistant states. <i>Diabetes/metabolism Reviews</i> , 1989, 5, 711-726.	0.2	62
263	Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: Contributions of excessive hepatic glucose production and impaired tissue glucose uptake. <i>Metabolism: Clinical and Experimental</i> , 1989, 38, 387-395.	1.5	492
264	Differential effects of insulin and hyperglycemia on intracellular glucose disposition in humans. <i>Metabolism: Clinical and Experimental</i> , 1989, 38, 459-465.	1.5	30
265	Metabolic basis of obesity and noninsulin-dependent diabetes mellitus. <i>Diabetes/metabolism Reviews</i> , 1988, 4, 727-747.	0.2	117
266	The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. <i>Metabolism: Clinical and Experimental</i> , 1988, 37, 79-85.	1.5	268
267	The theoretical bases of indirect calorimetry: A review. <i>Metabolism: Clinical and Experimental</i> , 1988, 37, 287-301.	1.5	1,425
268	Inadvertent Catheterization of the Internal Thoracic Vein Mimicking Pulmonary Embolism: A Case Report. <i>Journal of Parenteral and Enteral Nutrition</i> , 1988, 12, 221-222.	1.3	12
269	The kinetics of insulin in man. I. General aspects. <i>Diabetes/metabolism Reviews</i> , 1987, 3, 335-363.	0.2	75
270	The kinetics of insulin in man. II. Role of the liver. <i>Diabetes/metabolism Reviews</i> , 1987, 3, 365-397.	0.2	98



#	ARTICLE	IF	CITATIONS
271	Regulation of hepatic glucose metabolism in humans. <i>Diabetes/metabolism Reviews</i> , 1987, 3, 415-459.	0.2	139
272	Insulin Resistance in Essential Hypertension. <i>New England Journal of Medicine</i> , 1987, 317, 350-357.	13.9	2,338
273	Effect of bicycle exercise on insulin absorption and subcutaneous blood flow in the normal subject. <i>Clinical Physiology</i> , 1982, 2, 59-70.	0.7	34
274	The role of fractional glucose extraction in the regulation of splanchnic glucose metabolism in normal and diabetic man. <i>Metabolism: Clinical and Experimental</i> , 1980, 29, 28-35.	1.5	117
275	LACK OF A GASTROINTESTINAL MEDIATOR OF INSULIN ACTION IN MATURITY-ONSET DIABETES. <i>Lancet</i> , The, 1978, 312, 1077-1079.	6.3	32